Paquinimod [248282-01-1]
Cat# T7310-1mg
Size : 1mg
Marca : TargetMol
Paquinimod (Synonyms: ABR 25757)
Paquinimod
Copy Product InfoSynonyms ABR 25757
Cas No. 248282-01-1
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.79%
Color:White
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Paquinimod (ABR 25757) is a S100A9 inhibitor preventing S100A9 binding to TLR-4. |
| In vivo | Prophylactic treatment of paquinimod reduces synovial activation, osteophyte formation and cartilage damage in experimental OA with high synovial activation (CIOA) and ameliorates pathological effects of S100A9 in OA synovium ex vivo[1].Treatment with paquinimod reduces skin fibrosis measured as reduction of skin thickness and decreased number of myofibroblasts and total hydroxyproline content. The effect on fibrosis was associated with a polarization of macrophages in the skin from a pro-fibrotic M2 to a M1 phenotype. Paquinimod treatment also resulted in a reduced TGFβ-response in the skin and an abrogation of the increased auto-antibody production in this SSc model[1]. |
| Animal Research | Two OA mouse models differing in level of synovial activation were treated prophylactic with paquinimod. Synovial thickening, osteophyte size and cartilage damage were measured histologically, using an arbitrary score, adapted Pritzker OARSI score or imaging software, respectively. Human OA synovia were stimulated with S100A9, with or without paquinimod[1].Seven weeks old female B6.Cg-Fbn1(Tsk)/J (Tsk-1) mice were treated with vehicle or paquinimod at the dose of 5 or 25mg/kg/day in the drinking water for 8 weeks. The effect of paquinimod on the level of skin fibrosis and on different subpopulations within the myeloid cell compartment in skin biopsies were evaluated by using histology, immunohistochemisty, a hydroxyproline assay and real-time PCR. Furthermore, the level of IgG in serum from treated animals was also analysed. The statistical analyses were performed using Mann-Whitney nonparametric two tailed rank test[1]. |
| Synonyms | ABR 25757 |
| Molecular Weight | 350.41 |
| Formula | C21H22N2O3 |
| Cas No. | 248282-01-1 |
| Smiles | CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1 |
| Relative Density. | 1.267g/cm3 |
| Storage | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 123 mg/mL (351.02 mM), Sonication is recommended.  H2O: < 1 mg/mL (insoluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 12.5 mg/mL (35.67 mM), Suspension. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||